Showing results (11-20 of 49) with videos related to
Sort By:
Pageof 5
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2021
Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS TrialSophie Marguet, Antoine Adenis, Stéphanie Delaine-Clisant, et al.BMC Medical Research Methodology|March 31, 2016
Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysisBéranger Lueza, Federico Rotolo, Julia Bonastre, et al.Social Science & Medicine (1982)|December 24, 2019
Imperfect biomarkers for adjuvant chemotherapy in early stage breast cancer with good prognosisCatherine Bourgain, Lionel Pourtau, Chafika Mazouni, et al.Leukemia Research|May 8, 2018
The rising prevalence of chronic myeloid leukemia in FranceMarc Delord, Stéphanie Foulon, Jean-Michel Cayuela, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancerJulia Bonastre, Sophie Marguet, Beranger Lueza, et al.Plos One|March 10, 2016
Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case StudyBéranger Lueza, Audrey Mauguen, Jean-Pierre Pignon, et al.BMC Cancer|November 5, 2016
A prospective multicenter study on bladder cancer: the COBLAnCE cohortSimone Benhamou, Julia Bonastre, Karine Groussard, et al.BMJ Open|April 6, 2016
Dead space closure with quilting suture versus conventional closure with drainage for the prevention of seroma after mastectomy for breast cancer (QUISERMAS): protocol for a multicentre randomised controlled trialLobna Ouldamer, Julia Bonastre, Solène Brunet-Houdard, et al.Health Policy (Amsterdam, Netherlands)|December 10, 2013
Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals?Julia Bonastre, Julie Chevalier, Chantal Van der Laan, et al.ERJ Open Research|April 28, 2020
A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancerClémence Legoupil, Didier Debieuvre, Aurelien Marabelle, et al.Pageof 5